Your browser doesn't support javascript.
loading
Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
Gao, Ning; McLeod, Sarah M; Hajec, Laurel; Olivier, Nelson B; Lahiri, Sushmita D; Bryan Prince, D; Thresher, Jason; Ross, Philip L; Whiteaker, James D; Doig, Peter; Li, Amanda Haixi; Hill, Pamela J; Cornebise, Mark; Reck, Folkert; Hale, Michael R.
Afiliación
  • Gao N; Discovery Sciences, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA. Electronic address: ning.gao@astrazeneca.com.
  • McLeod SM; Department of Bioscience, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Hajec L; Department of Bioscience, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Olivier NB; Discovery Sciences, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Lahiri SD; Department of Bioscience, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Bryan Prince D; Discovery Sciences, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Thresher J; Department of Bioscience, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Ross PL; Discovery Sciences, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Whiteaker JD; Department of Bioscience, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Doig P; Discovery Sciences, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Li AH; Department of Chemistry, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Hill PJ; Department of Chemistry, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Cornebise M; Department of Chemistry, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Reck F; Department of Chemistry, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Hale MR; Department of Chemistry, Infection Innovative Medicine Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
Protein Expr Purif ; 104: 57-64, 2014 12.
Article en En | MEDLINE | ID: mdl-25240855
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Proteínas Bacterianas / Proteínas de Escherichia coli / Proteínas Asociadas a Resistencia a Múltiples Medicamentos / Amidohidrolasas Idioma: En Revista: Protein Expr Purif Asunto de la revista: BIOLOGIA MOLECULAR Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Proteínas Bacterianas / Proteínas de Escherichia coli / Proteínas Asociadas a Resistencia a Múltiples Medicamentos / Amidohidrolasas Idioma: En Revista: Protein Expr Purif Asunto de la revista: BIOLOGIA MOLECULAR Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos